The US review of Eli Lilly & Co.’s lasmiditan new drug application (NDA) will be the first significant test of FDA's final guidance on development of acute treatments for migraine.
Released in February 2018, the guidance is part of the agency's modernization of the Center for Drug Evaluation and Research's Office of New Drugs so that it has a...